Structured evidence table for Calcium Fracture Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Calcium Fracture Randomized Trial | Summary This review summarizes current evidence on scoring balloons, cutting balloons, and ultra-high-pressure (OPN NC) balloons and aims to define their specific role and indications in the treatment of calcified coronary disease. | 3 | Colletti G (2026) | Calcium modifying dedicated balloons: a contemporary review. |
| Calcium Fracture Randomized Trial | Background Calcified coronary lesions are a major challenge in percutaneous coronary intervention (PCI), frequently leading to stent underexpansion, restenosis, and adverse events. | 3 | Colletti G (2026) | Calcium modifying dedicated balloons: a contemporary review. |
| Calcium Fracture Randomized Trial | While multiple technologies exist for plaque modification, there remains a critical need for clear guidance on the optimal selection and use of dedicated balloon-based devices. | 3 | Colletti G (2026) | Calcium modifying dedicated balloons: a contemporary review. |
| Calcium Fracture Randomized Trial | Accordingly, contemporary guidelines no longer recommend IN-CAL as first-line treatment for chronic osteoporosis, and concerns regarding a potential malignancy signal further limited long-term use. | 3 | Ahmad Areeb (2026) | Revisiting Intranasal Salmon Calcitonin: Historical Osteoporosis Evidence and a Potential Role in Acute Orthopaedic Pain Management |
| Calcium Fracture Randomized Trial | 18 A landmark review by Plosker and McTavish summarized the pharmacologic and clinical evidence for IN-CAL through the mid-1990s. | 3 | Ahmad Areeb (2026) | Revisiting Intranasal Salmon Calcitonin: Historical Osteoporosis Evidence and a Potential Role in Acute Orthopaedic Pain Management |
| Calcium Fracture Randomized Trial | The present review builds upon this foundation by contextualizing historical data and synthesizing subsequent evidence across 3 domains: (1) pharmacology and mechanisms; (2) established and preventive osteoporosis; and (3) acute orthopaedic applications, with particular emphasis on analgesia and time-dependent therapeutic effects. | 3 | Ahmad Areeb (2026) | Revisiting Intranasal Salmon Calcitonin: Historical Osteoporosis Evidence and a Potential Role in Acute Orthopaedic Pain Management |
| Calcium Fracture Randomized Trial | 1 3 - 4 5 , Intranasal salmon calcitonin (IN-CAL) is a peptide antiresorptive agent historically used in the management of postmenopausal osteoporosis, where early randomized trials demonstrated lumbar spine-specific increases in bone mineral density (BMD) with minimal peripheral effects. | 3 | Ahmad Areeb (2026) | Revisiting Intranasal Salmon Calcitonin: Historical Osteoporosis Evidence and a Potential Role in Acute Orthopaedic Pain Management |
Source documents